Research graph
References from Synthetic consensus DNA vaccines against Merkel cell polyomavirus large and small T antigens induce robust polyfunctional T cell responses. Local targets link to admitted publications; unresolved targets remain external evidence.
Merkel cell carcinoma—update on diagnosis, management and future perspectives
10.3390/cancers15010103 · 2022 · External reference
Merkel cell carcinoma: current US incidence and projected increases based on changing demographics
10.1016/j.jaad.2017.10.028 · 2018 · External reference
Polyomavirus-negative Merkel cell carcinoma: a more aggressive subtype based on analysis of 282 cases using multimodal tumor virus detection
10.1016/j.jid.2016.10.028 · 2017 · External reference
Diagnosis and treatment of Merkel cell carcinoma. European consensus-based interdisciplinary guideline
10.1016/j.ejca.2015.06.131 · 2015 · External reference
Merkel cell carcinoma, version 1.2024
10.6004/jnccn.2024.0002 · 2024 · External reference
Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumab
10.1186/s40425-018-0404-0 · 2018 · External reference
Merkel cell polyomavirus-specific CD8+ and CD4+ T-cell responses identified in Merkel cell carcinomas and blood
10.1158/1078-0432.ccr-11-1513 · 2011 · External reference
Non-comparative, open label, multiple cohort, phase 1/2 study to evaluate nivolumab in patients with virus-associated tumors (CheckMate 358): efficacy and safety in Merkel cell carcinoma
10.1158/1538-7445.am2017-ct074 · 2017 · External reference
PD-1 blockade with pembrolizumab in advanced Merkel-cell carcinoma
10.1056/nejmoa1603702 · 2016 · External reference
Durable tumor regression and overall survival in patients with advanced Merkel cell carcinoma receiving pembrolizumab as first-line therapy
10.1200/jco.18.01896 · 2019 · External reference
Efficacy and safety of avelumab treatment in patients with metastatic Merkel cell carcinoma: experience from a global expanded access program
10.1136/jitc-2019-000313 · 2020 · External reference
First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel 200): primary and biomarker analyses of a phase II study
10.1136/jitc-2021-002646 · 2021 · External reference
Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial
2020 · External reference
Unresolved reference
2025 · External reference
Molecular mechanisms of Merkel cell polyomavirus transformation and replication
10.1146/annurev-virology-011720-121757 · 2021 · External reference
DNA-based immunotherapy for cancer: in vivo approaches for recalcitrant targets
10.1016/j.ymthe.2025.04.008 · 2025 · External reference
DNA vaccines: prime time is now
10.1016/j.coi.2020.01.006 · 2020 · External reference
synDNA vaccine against TCR chains and neoantigens for T cell lymphoma therapy
10.1007/s00262-026-04302-5 · 2026 · External reference
Induction of antitumor immunity in vivo following delivery of a novel HPV-16 DNA vaccine encoding an E6/E7 fusion antigen
10.1016/j.vaccine.2008.10.078 · 2009 · External reference
Cellular immunity induced by a novel HPV18 DNA vaccine encoding an E6/E7 fusion consensus protein in mice and rhesus macaques
10.1016/j.vaccine.2008.03.069 · 2008 · External reference
A designer cross-reactive DNA immunotherapeutic vaccine that targets multiple MAGE-A family members simultaneously for cancer therapy
10.1158/1078-0432.ccr-18-1013 · 2018 · External reference
Novel synthetic DNA immunogens targeting latent expressed antigens of Epstein-Barr virus elicit potent cellular responses and inhibit tumor growth
10.3390/vaccines7020044 · 2019 · External reference
DNA immunotherapy targeting BARF1 induces potent anti-tumor responses against Epstein-Barr-virus-associated carcinomas
10.1016/j.omto.2021.12.017 · 2021 · External reference
A synDNA vaccine delivering neoAg collections controls heterogenous, multifocal murine lung and ovarian tumors via robust T cell generation
10.1016/j.omto.2021.04.005 · 2021 · External reference
Immune therapy targeting E6/E7 oncogenes of human papillomavirus type 6 (HPV-6) reduces or eliminates the need for surgical intervention in the treatment of HPV-6 associated recurrent respiratory papillomatosis
10.3390/vaccines8010056 · 2020 · External reference
Safety and efficacy of MEDI0457 plus durvalumab in patients with human papillomavirus–associated recurrent/metastatic head and neck squamous cell carcinoma
10.1158/1078-0432.ccr-22-1987 · 2023 · External reference
INOVIO's VGX-3100 demonstrates positive phase 2 efficacy in treatment of precancerous anal dysplasia caused by HPV-16/18
2020 · External reference
VGX-3100 and electroporation in treating patients with HIV-positive high-grade anal lesions
2024 · External reference
Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial
10.1016/s0140-6736(15)00239-1 · 2015 · External reference
Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1/2 trial
10.1038/s41591-024-02894-y · 2024 · External reference
Merkel cell polyomavirus large T antigen disrupts host genomic integrity and inhibits cellular proliferation
10.1128/jvi.01216-13 · 2013 · External reference
T antigen mutations are a human tumor-specific signature for Merkel cell polyomavirus
10.1073/pnas.0806526105 · 2008 · External reference
Clonal integration of a polyomavirus in human Merkel cell carcinoma
10.1126/science.1152586 · 2008 · External reference
NetMHCpan, a method for quantitative predictions of peptide binding to any HLA-A and -B locus protein of known sequence
10.1371/journal.pone.0000796 · 2007 · External reference
Development of a DNA vaccine targeting Merkel cell polyomavirus
10.1016/j.vaccine.2011.12.072 · 2012 · External reference
Creation of a Merkel cell polyomavirus small T antigen-expressing murine tumor model and a DNA vaccine targeting small T antigen
10.1186/2045-3701-3-29 · 2013 · External reference
LAMP1 targeting of the large T antigen of Merkel cell polyomavirus results in potent CD4 T cell responses and tumor inhibition
10.3389/fimmu.2023.1253568 · 2023 · External reference
Adjuvant personalized multivalent neoantigen DNA vaccination for MGMT unmethylated glioblastoma: a phase 1 trial
10.1038/s43018-026-01163-w · 2026 · External reference
Viral oncoprotein antibodies as a marker for recurrence of Merkel cell carcinoma: a prospective validation study
10.1002/cncr.30475 · 2017 · External reference
Characterization of the major histocompatibility complex class I deficiencies in B16 melanoma cells
2001 · External reference
Large and small t antigens of merkel cell polyomavirus, nucleic acid constructs and vaccines made therefrom, and methods of using same
2023 · External reference
